NCT07462000

Brief Summary

This observational study will compare proteomic and elemental profiles of aqueous humor and ocular tissues in patients with primary open-angle glaucoma (POAG) and cataract versus cataract controls without glaucoma. Samples collected during standard surgery will be analyzed using LC-MS/MS and ICP-MS. The goal is to identify glaucoma-associated molecular patterns with potential diagnostic or prognostic relevance.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
17mo left

Started Jan 2026

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress29%
Jan 2026Nov 2027

Study Start

First participant enrolled

January 21, 2026

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

February 9, 2026

Completed
29 days until next milestone

First Posted

Study publicly available on registry

March 10, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 21, 2027

Expected
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2027

Last Updated

March 10, 2026

Status Verified

January 1, 2026

Enrollment Period

1 year

First QC Date

February 9, 2026

Last Update Submit

March 6, 2026

Conditions

Keywords

POAGGlaucomaCataractPrimary Open-Angle GlaucomaProteomicsAqueous HumorLC-MS/MSDeep Sclerectomy

Outcome Measures

Primary Outcomes (5)

  • IOP

    Intraocular Pressure

    Through study completion, an average of 1 year

  • Visual Field

    Visual Field of the mean defect (MD)

    Through study completion, an average of 1 year

  • BCVA

    Best-corrected visual acuity

    Through study completion, an average of 1 year

  • Protein expression

    Measured by ICP-MS/LC-MS

    Through study completion, an average of 1 year

  • RNFL

    Retinal Nerve Fiber Layer (OCT)

    Through study completion, an average of 1 year

Secondary Outcomes (1)

  • Medications

    Through study completion, an average of 1 year

Study Arms (2)

Glaucoma + Cataract Group

EXPERIMENTAL
Procedure: Phacoemulsification With Intraocular Lens Implantation and Deep Sclerectomy

Cataract Control Group

ACTIVE COMPARATOR
Procedure: Phacoemulsification With Intraocular Lens Implantation

Interventions

Standard-of-care cataract surgery (phacoemulsification with intraocular lens implantation). Intraoperative collection of aqueous humor and routinely removed ocular tissue (anterior lens capsule) is performed for research analyses.

Cataract Control Group

Standard-of-care combined cataract surgery (phacoemulsification with intraocular lens implantation) performed together with deep sclerectomy for glaucoma management. Intraoperative collection of aqueous humor and routinely removed ocular tissues (such as sclera and anterior lens capsule) is performed for research analyses.

Glaucoma + Cataract Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years.
  • Scheduled for cataract surgery (phacoemulsification with intraocular lens implantation).
  • Ability to provide written informed consent.
  • For glaucoma arm: diagnosis of primary open-angle glaucoma (POAG) with coexisting cataract, and planned combined cataract surgery with glaucoma procedure.
  • For control arm: cataract without glaucoma and without other significant ocular pathology.

You may not qualify if:

  • Age \< 18 years.
  • Pregnancy or breastfeeding.
  • Advanced visual impairment in the study eye (visual aquity worse than counting fingers).
  • Any glaucoma type other than primary open-angle glaucoma (e.g., angle-closure, secondary, neovascular glaucoma).
  • History of intraocular surgery in the study eye (including glaucoma surgery), vitreoretinal surgery, corneal transplantation, or refractive surgery.
  • Active or previous uveitis.
  • Other significant chronic ocular disease in the study eye (other than cataract and POAG in the glaucoma arm).
  • Inability to comply with study procedures or follow-up visits.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Military Institute of Medicine - National Research Institute

Warsaw, Poland

RECRUITING

University of Warsaw

Warsaw, Poland

RECRUITING

MeSH Terms

Conditions

Glaucoma, Open-AngleCataractGlaucoma

Interventions

PhacoemulsificationLens Implantation, Intraocular

Condition Hierarchy (Ancestors)

Ocular HypertensionEye DiseasesLens Diseases

Intervention Hierarchy (Ancestors)

Cataract ExtractionRefractive Surgical ProceduresOphthalmologic Surgical ProceduresSurgical Procedures, OperativeUltrasonic Surgical Procedures

Study Officials

  • Marek Rękas, MD, PhD

    Military Institute of Medicine National Research Institute

    PRINCIPAL INVESTIGATOR
  • Ewa Bulska, PhD

    University of Warsaw

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Marek Rękas, MD, PhD

CONTACT

Wojciech Mazurek, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Parallel-group design comparing patients with glaucoma and cataract to cataract-only controls. Biological samples are collected intraoperatively during standard-of-care surgery for laboratory analysis.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 9, 2026

First Posted

March 10, 2026

Study Start

January 21, 2026

Primary Completion (Estimated)

January 21, 2027

Study Completion (Estimated)

November 30, 2027

Last Updated

March 10, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations